Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Atherosclerosis Drugs Market Valued at Present and by 2029?

The market for atherosclerosis medicine has seen consistent growth in the past few years. The market is predicted to expand from $49.89 billion in 2024 to $50.91 billion in 2025, with a compound annual growth rate (CAGR) of 2.0%. The growth observed in the historic period can be credited to factors such as cholesterol management, control of blood pressure, anti-smoking initiatives, research and development, as well as improvements in diagnosis.

In the coming years, the market size for atherosclerosis drugs is anticipated to experience consistent expansion. It is forecasted to proliferate to “$58.36 billion by 2029, with a compound annual growth rate (CAGR) of 3.5%. This growth over the predicted period is linked to the emergence of new therapies, precision medicine, immunotherapy and inflammation control, advancements in lipid management, and regulatory support. Key trends for the forecast period consist of biologic therapies, gene alteration and gene therapy, multifaceted therapies, individualized treatment strategies, telemedicine and distant monitoring.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp

#What Drivers Are Influencing Growth In The Atherosclerosis Drugs Market?

The increase in cases of cardiovascular diseases is projected to spur the growth of the atherosclerosis drug market. Cardiovascular diseases encompass all disorders impacting the heart and blood vessels, while atherosclerosis denotes the accumulation of fats, cholesterol, and other substances on a person’s artery walls. Atherosclerosis, marked by the formation of plaque inside the arteries, leads to cardiovascular diseases such as stroke and coronary heart disease. Atherosclerosis drugs play a crucial role in managing these diseases by mitigating the risk of complications and addressing the underlying conditions like cholesterol levels elevation and blood clot formation. As per the Minnesota Department of Health’s data in September 2024, a state health agency based in the US, nearly 30% of adults in Minnesota, approximating to 1.4 million people, were reported to have high blood pressure in 2023. Further, hypertensive diseases caused or contributed to 14,225 deaths in 2022, accounting for almost 28% of the total deaths in the state. Thus, the high incidence rate of cardiovascular diseases will fuel the growth of the atherosclerosis drug market.

What Are The Main Segments Identified In The Atherosclerosis Drugs Market Research?

The atherosclerosis drugs market covered in this report is segmented –

1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor

2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements

3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril

4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics

5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants

6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol

7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil

8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors

What Upcoming Trends Are Expected To Impact The Atherosclerosis Drugs Market Globally?

Forward-thinking product innovation is becoming an increasingly prevalent trend within the atherosclerosis drugs market. Leading corporations within this sector are pursuing the creation of innovative drugs and striving to gain approvals in order to maintain their market stature. As a case in point, Novo Nordisk A/S, a healthcare enterprise based in Denmark, declared in March 2024 that it had gained approval for its drug, Wegovy (semaglutide), meant to minimize cardiovascular risk in overweight or obese individuals. This marks the first medication approved specifically to mitigate major cardiovascular incidents in adults who are overweight or obese with an existing cardiovascular disease, offering a fresh treatment option for this vulnerable population group. The two-fold benefits of this drug not only contribute to the management of obesity but are also instrumental in averting severe cardiovascular complications, thereby enhancing potential patient results and extending lifespan.

Which Companies Play A Key Role In The Development Of The Atherosclerosis Drugs Market?

Major companies operating in the atherosclerosis drugs market include Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co.Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc., Anthera Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

What Are The Key Regional Developments Shaping The Atherosclerosis Drugs Market?

North America was the largest region in the atherosclerosis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12621&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model